Research Interests
The group led by Chen Xiaoguang focuses on the mechanism related to cancer, autoimmunity disease and rental disease and develops novel therapeutic medicine, especially for cancer therapy. Their research areas include molecular targets, immunotherapy-related checkpoint inhibitors and metabolism checkpoint inhibitors such as PARP1/2, PI3K, STAT3, HSP90, PD1/PD-L1, IOO1/TDO, LAG3, ACAT1,etc.
